We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
-24.15%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.88B
AUM Growth
-$596M
(-24%)
Cap. Flow
+$67.8M
Cap. Flow
% of AUM
3.61%
Top 10 Holdings %
Top 10 Hldgs %
70.78%
Holding
37
New
1
Increased
21
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Puma Biotechnology
PBYI
|
+$34.8M |
| 2 |
STAAR Surgical
STAA
|
+$24.4M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$11.4M |
| 4 |
CELG
Celgene Corp
CELG
|
+$7.63M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$6.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$25.3M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$6.73M |
| 3 |
TRVN
Trevena, Inc.
TRVN
|
+$724K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rigel Pharmaceuticals
RIGL
$782M
| $9.17M | 0.49% |
398,595
+1,986
| +0.5% | +$56K |
|
|
SHPG
27
DELISTED
Shire pic
SHPG
| $8.34M | 0.44% |
47,938
-144,800
| -75% | -$25.3M |
|
|
DRNA
28
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.36M | 0.29% |
500,913
| – | – |
|
|
ALIM
29
DELISTED
Alimera Sciences
ALIM
| $2.16M | 0.12% |
200,920
| – | – |
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $1.08M | 0.06% |
29,500
| – | – |
|
31
Cytokinetics
CYTK
$10.5B
| $782K | 0.04% |
123,686
| – | – |
|
|
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $483K | 0.03% |
33,214
| – | – |
|
|
ACGN
33
DELISTED
Aceragen Inc
ACGN
| $213K | 0.01% |
4,537
| – | – |
|
|
SPHS
34
DELISTED
Sophiris Bio, Inc.
SPHS
| $205K | 0.01% |
247,000
| – | – |
|
|
MLNT
35
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $40K | ﹤0.01% |
10,138
| – | – |
|
36
Ocugen
OCGN
$475M
| $27K | ﹤0.01% |
5,049
| – | – |
|
|
TRVN
37
DELISTED
Trevena, Inc.
TRVN
| – | – |
-546
| Closed | -$724K |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q4 2018 Portfolio in Review
As of Q4 2018, Palo Alto Investors held 37 positions worth $1.88B, down 24% from $2.47B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Palo Alto Investors deployed $67.8M of net new capital in Q4 2018, opening 1 new position and adding to 21 existing holdings. Its largest new stake was Puma Biotechnology: 1,159,900 shares worth $23.6M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.
On the sell side, the largest reduction was Shire pic, an estimated $25.3M trimmed.
- Palo Alto Investors's largest Q4 2018 buy was Puma Biotechnology: 1,159,900 shares worth $23.6M.
- Palo Alto Investors added most to STAAR Surgical in Q4 2018, an estimated $24.4M increase.
- Palo Alto Investors's biggest Q4 2018 reduction was Shire pic, cutting an estimated $25.3M.
- Palo Alto Investors fully exited Trevena, Inc. in Q4 2018, selling an estimated $724K.
- Palo Alto Investors's ten largest holdings make up 71% of its $1.88B portfolio in Q4 2018.
- Palo Alto Investors opened 1 new position and closed 1 in Q4 2018.
- Palo Alto Investors's portfolio value fell 24% quarter-over-quarter to $1.88B.
Based on Palo Alto Investors's 13F filing for Q4 2018, filed 14 Feb 2019.